Literature DB >> 25740454

Significant prognostic factors for completely resected pN2 non-small cell lung cancer without neoadjuvant therapy.

Hirofumi Uehara1, Masayuki Nakao, Mingyon Mun, Ken Nakagawa, Makoto Nishio, Yuichi Ishikawa, Sakae Okumura.   

Abstract

PURPOSE: To identify prognostic factors for pathologic N2 (pN2) non-small cell lung cancer (NSCLC) treated by surgical resection.
METHODS: Between 1990 and 2009, 287 patients with pN2 NSCLC underwent curative resection at the Cancer Institute Hospital without preoperative treatment.
RESULTS: The 5-year overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) rates were 46%, 55% and 24%, respectively. The median follow-up time was 80 months. Multivariate analysis identified four independent predictors for poor OS: multiple-zone mediastinal lymph node metastasis (hazard ratio [HR], 1.616; p = 0.003); ipsilateral intrapulmonary metastasis (HR, 1.042; p = 0.002); tumor size >30 mm (HR, 1.013; p = 0.002); and clinical stage N1 or N2 (HR, 1.051; p = 0.030). Multivariate analysis identified three independent predictors for poor RFS: multiple-zone mediastinal lymph node metastasis (HR, 1.457; p = 0.011); ipsilateral intrapulmonary metastasis (HR, 1.040; p = 0.002); and tumor size >30 mm (HR, 1.008; p = 0.032).
CONCLUSION: Multiple-zone mediastinal lymph node metastasis, ipsilateral intrapulmonary metastasis, and tumor size >30 mm were common independent prognostic factors of OS, CSS, and RFS in pN2 NSCLC.

Entities:  

Mesh:

Year:  2015        PMID: 25740454      PMCID: PMC4904870          DOI: 10.5761/atcs.oa.14-00262

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  14 in total

1.  The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer.

Authors:  Panagiotis Misthos; Evangelos Sepsas; John Kokotsakis; Ion Skottis; Achilleas Lioulias
Journal:  Ann Thorac Surg       Date:  2008-11       Impact factor: 4.330

2.  Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.

Authors:  Makoto Sonobe; Masashi Kobayashi; Masashi Ishikawa; Ryutaro Kikuchi; Ei Nakayama; Tsuyoshi Takahashi; Toshi Menju; Kazumasa Takenaka; Ryo Miyahara; Cheng-Long Huang; Kenichi Okubo; Toru Bando; Hiroshi Date
Journal:  Ann Surg Oncol       Date:  2011-05-24       Impact factor: 5.344

Review 3.  Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

4.  Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis.

Authors:  Marc Riquet; Jalal Assouad; Patrick Bagan; Christophe Foucault; Françoise Le Pimpec Barthes; Antoine Dujon; Claire Danel
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

5.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

6.  Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery.

Authors:  H Wada; S Hitomi; T Teramatsu
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

7.  A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304).

Authors:  Hirohito Tada; Ryosuke Tsuchiya; Yukito Ichinose; Teruaki Koike; Nobuhiro Nishizawa; Kanji Nagai; Harubumi Kato
Journal:  Lung Cancer       Date:  2004-02       Impact factor: 5.705

8.  Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005.

Authors:  Daniel Morgensztern; Saiama Waqar; Janakiraman Subramanian; Feng Gao; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2009-12       Impact factor: 15.609

9.  Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Nithya Ramnath; Thomas J Dilling; Loren J Harris; Anthony W Kim; Gaetane C Michaud; Alex A Balekian; Rebecca Diekemper; Frank C Detterbeck; Douglas A Arenberg
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Size of Stage IIIA primary lung cancers and survival: a surveillance, epidemiology and end results database analysis.

Authors:  Steven Maximus; Danh V Nguyen; Yi Mu; Royce F Calhoun; David T Cooke
Journal:  Am Surg       Date:  2012-11       Impact factor: 0.688

View more
  4 in total

1.  Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.

Authors:  Whitney S Brandt; Wanpu Yan; Jonathan E Leeman; Kay See Tan; Bernard J Park; Prasad S Adusumilli; Matthew J Bott; Daniela Molena; James Isbell; Jamie Chaft; Andreas Rimner; David R Jones
Journal:  Ann Thorac Surg       Date:  2018-05-26       Impact factor: 4.330

2.  Five-year survival analysis and prognostic factors in patients operated on for non-small cell lung cancer with N2 disease.

Authors:  Mariusz Łochowski; Barbara Łochowska; Marek Rębowski; Daniel Brzeziński; Bartosz Cieślik-Wolski; Józef Kozak
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis.

Authors:  Tingting Liu; Yanshu Mu; Jun Dang; Guang Li
Journal:  J Cancer       Date:  2019-06-24       Impact factor: 4.207

4.  Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer.

Authors:  Qiongjie Yu; Xuedan Du; Zhen Fang; Xiaolu Mao; Jinting Wu; Bin Wang; Wenfeng Li
Journal:  Cancer Manag Res       Date:  2021-11-18       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.